secwatch / observer
8-K filed November 17, 2022, 6:59 PM ET ticker TNYA CIK 0001858848
other material confidence high sentiment neutral materiality 0.70

Tenaya Therapeutics prices public offering of ~28.85M shares/warrants for ~$75M gross proceeds

Tenaya Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tenaya Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Piper Sandler & Co., as representatives of the several underwriters named therein valued at approximately $75.0 million (effective 2022-11-16).

Action
entry
Agreement
underwriting
Counterparty
Morgan Stanley & Co. LLC and Piper Sandler & Co., as representatives of the several underwriters named therein
Value
approximately $75.0 million
Effective
2022-11-16
Exact text from the filing
On November 16, 2022, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 22,613,307 shares of the Company’s common stock, par value $0.0001 per share, at a price to the public of $2.60 per share (the “Underwritten Shares”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 6,236,693 shares of the Company’s common stock at a price to the public of $2.599 per underlying share.
View on SEC.gov

Browse all material agreements →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-287687
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.